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Pharmacokinetic models are applied to determine the drug distribution in the organism with respect to a given 
administration. Models based on body anatomy and physiology can provide an accurate description of drug 
concentrations reached in specific organs and tissues of mammals. This article proposes a model based on 
mammalian anatomy and physiology to predict the biodistribution in mice of sorafenib, an anti-cancer drug, 
with specific attention to the concentration reached in the liver, as that is the action site in case of 
hepatocellular carcinoma treatment. The model reveals a close correspondence respect to experimental 
concentration data in the organism and also assesses with good fidelity the enterohepatic circulation, a 
phenomenon occurring at the liver-intestine level and that strongly characterizes sorafenib distribution. 
1. Introduction 
The pharmacological effect of drugs is directly related to the concentrations that are reached in blood and 
tissues of living beings. The assessment of these concentration values results a fundamental aspect in all the 
scientific areas related to health care. The most common technique to determine the drug concentration 
requires sampling the reference tissues at specific times and measuring it in laboratory. This practice carries 
along a large number of drawbacks, as it requires invasive and repeated sampling of tissues, expensive 
measures and analysis, and a large batch of pharmacokinetic samples. To overcome these limitations, 
computer programs have become more popular. They are based on mathematical models able to predict the 
dynamics of drug concentration in the organism. 
Mathematical pharmacokinetic models, despite their original simplicity (Wagner, 1993), are now highly 
detailed and can evaluate the drug concentration in organs and tissues of the target body. These advanced 
reproductions were christened Physiologically Based Pharmacokinetic (PBPK) models, and even if they were 
first introduced by Teorell (1937), only recently they have become extensively used and interesting for 
pharmaceutical companies to submit reports to regulatory agencies (Huang et al., 2013). In order to accurately 
evaluate the pharmacokinetics, PBPK models are based on the assumption that the body can be described by 
a certain number of interconnected compartments, each standing for a specific organ or tissue. In order to 
preserve the consistency with real anatomy and physiology, the compartment connections are based on the 
real anatomical structure. 
The ambitious goal of PBPK modeling is to reduce dramatically the necessity to run experimental 
pharmacokinetic evaluations and also to be a sophisticated and flexible tool for in silico simulation of the 
behaviour of new drug molecules in the human body. PBPK models can also facilitate and speed up the 
research activity of new active principles. 
An aspect limiting the extensive use of PBPK models is the necessity of a large amount of detailed information 
regarding specific properties and features of organs and tissues (e.g., cells membrane permeability, blood 
volumetric fluxes, drug metabolic reactions, just to mention a few), which can hardly be experimentally 
measured or theoretically assessed thus resulting often as unknown values. 
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Given this background, the final formulation of the PBPK model consists in a system of Ordinary Differential 
Equations (ODEs) that describes the drug mass balances in every modeled compartment. Figure 1 shows the 
schematic representation of mammalian body according to its anatomy and physiology. The interconnected 
compartments represent lumped versions of both organs and tissues and reproduce how the topological 
structure is interested by the quite complex phenomena involved in the dynamic distribution of drug in the 
body. 
Pharmacokinetic models help understanding better how drugs possibly distribute through, metabolize in, and 
finally are excreted by the body. Specifically, they are quite promising and interesting as far as anti-cancer 
drugs are concerned. In fact, during clinical trials it is common practice to administer the studied drug to 
animals and human volunteers, but this is a critical issue in case of anti-cancer drugs because of the adverse 
side effects. In addition, the treating of carcinoma is a highly invasive practice, both in case of surgeries and 
pharmacological treatment. 
This article focuses on the cure of Hepatocellular Carcinoma (HCC), which is the most common type of liver 
cancer and the fifth more frequent malignancy worldwide (Abou-Alfa et al., 2006). The only effective ways to 
survive this disease are either surgical resection or liver transplantation (Llovet et al., 2000), with the conditio 
sine qua non for all these cases being the early diagnosis. When the disease is unresectable, the only therapy 
available is the pharmacological treatment, which may generally allow a life extension of few months. 
Sorafenib is a drug for the cure of renal and hepatic carcinoma, approved by both FDA and EMEA, and 
commercialized as Nexavar®. It acts as a multi-kinase inhibitor that targets tumor growth and angiogenesis 
(Akaza et al., 2007). 
2. State of the art 
The mechanistic approach to pharmacokinetic modeling started to be extensively applied with the work of 
Himmelstein and Lutz (1979); the following decades saw a strong growth of this scientific field. The work by 
Jain et al. (1981) is surely a milestone as it introduced innovative concepts that are still present in recent 
publications. That work proposed a complete whole-body PBPK model of the rat composed of 21 
compartments originating a system of 38 ODEs and 98 adaptive parameters. Some of those parameters were 
available in the literature but 37 had to be fitted by a regression routine. The application of such a complex 
model allows achieving the detailed description of the rat body, but implies some mathematical limitations, 
manly related to the large number of unknown adaptive parameters. Other PBPK models were proposed in 
the following years, where it is clear the attempt to reduce the complexity while preserving an extended 
anatomical and physiological consistency. 
Amongst pharmacokinetic (PK) models, it is interesting to highlight the presence of a large number of 
publications specifically devoted to the description of the oral absorption process. Yu et al. (1996a,b) 
published a detailed model of the gastrointestinal tract based on ten compartments, which resulted quite 
detailed. They introduced a system of 10 ODEs based on 18 adaptive parameters. That model, named CAT 
(from Compartmental Absorption and Transit), showed a good agreement with experimental data of human 
patients administered with different active principles. A subsequent version of CAT model was implemented in 
the Gastro Plus commercial software by Simulations Plus. That program is based on the ACAT (Advanced 
Compartmental Absorption and Transit) model, which features a detailed compartmental description of the 
gastrointestinal tracts (Agoram et al., 2001). 
Del Cont et al. (2014) proposed a comprehensive model that involves the physical processes, which 
determine the release of drugs from a polymeric matrix and the following intestinal absorption, and implements 
a complete description of the oral administration process. 
The difficulties connected with the model complexity and parameter identification of whole body PBPK 
simulations induced the implementation of reduced complexity models, which attempt to maintain the core 
anatomical and physiological consistency. This model reduction activity was mainly based on limiting and 
lumping together similar compartments so to reduce their total number and as a consequence the number of 
equations and parameters. Nestorov et al. (1998) and Pilari and Huisinga (2010) provide details about both 
lumping and model reduction activities. 
The work of Di Muria et al. (2010) summarizes some of the concepts reported in the previously cited works. 
There, a complete mammalian structure is obtained by modeling two lumped compartments, namely the 
Plasma (i.e., the blood and the largely-perfused organs/tissues) and the Tissues (i.e., blood scarcely-perfused 
organs/tissues). The PBPK model of Di Muria et al. (2010) considers seven compartments (i.e. gastric lumen, 
small intestine, large intestine, gastro intestinal circulatory system, liver, plasma, and other tissues). The 
corresponding mathematical formulation comprises 7 ODEs involving 22 physiological and pharmacokinetic 
parameters. 
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For what it concerns the sorafenib PK model, it is worth referring to two literature works. Jain et al. (2011) 
proposed a one compartment model with additional components to define the gastrointestinal absorption and 
the enterohepatic circulation. Pawaskar et al. (2013) realized a PBPK model capable to assess drug 
interactions between sorafenib and everolimus in mice; sorafenib was administered to BALB/c mice and 
samples were collected from blood and organs/tissues at different time interval. 
3. Methods 
The proposed model is derived from the original structure of Di Muria et al. (2010), but substantial variations 
are introduced to describe the gastrointestinal tract, the enterohepatic circulation (EHC), the plasma 
compartment, and the drug-protein binding properties. Figure 1 shows the model compartmental structure. 
 
Figure 1: PBPK model compartmental structure. 
Sorafenib is administered orally (ܲ. ܱ.). In case of mice, it is introduced directly in the stomach through gastric 
gavage. Then it crosses the two intestine tracts, i.e. small intestine (ܵܫܮ) and large intestine (ܮܫܮ). Finally, the 
residual part is excreted through the faeces (ܨா,௅ூ௅). ܵܫܮ is the main site of absorption of substances from the 
intestinal lumen into blood circulation. In mathematical terms, this occurs through the application of two mass 
transfer coefficients:	݇஺,ௌூ௅ for the absorption into blood, and ݇஼஺,ௌூ௅ for the counter-absorption into ܵܫܮ. A 
similar phenomenon characterizes the ܮܫܮ but with a minor contribution to the global intestinal absorption. 
Similarly, the related mass transfer coefficients are ݇஺,௅ூ௅ and ݇஼஺,௅ூ௅. 
To provide a consistent mathematical description of the ܵܫܮ, both time and spatial coordinates of drug 
concentration in the lumen should be taken into account. This can be achieved by modeling the lumen as a 
Plug Flow Reactor (PFR), where concentration varies axially. A simplified approach suggests approximating 
the PFR framework with a sufficiently high number of Continuous Stirred Tank Reactors (CSTRs) in series. 
The spatial discretization of the longitudinal coordinate allows preserving the ODE structure, thus avoiding any 
partial derivative equations. Generally speaking, the model is discretized into NR CSTRs (in our study we 
chose NR=7 as a suitable compromise between detail and efficiency), where the sum of the volumes of single 
reactors is equal to the total ܵܫܮ volume, while the mass transfer phenomena are considered in both directions 
(i.e. absorption and counter absorption) as discussed above. The parameter values are the same and kept 
constant for each reactor. The absorbed drug is collected into the so called Gastro-Intestinal Circulatory 
System (ܩܫ. ܥ. ܵ.), which represents the blood channels that receive substances from the intestine and deliver 
them to the liver through the portal vein. Once the drug reaches the liver, it is partially eliminated because of 
the metabolic activity in the hepatocytes. Mathematically, this is evaluated by the term ܥܮு standing for 
hepatic clearance, which is the volume of blood purified from the drug in the unit of time. Blood reaches the 
liver either through the portal vein (ܳ௉௏) or via the hepatic artery (ܳு஺) and leaves that organ via the venous 
channel called hepatic vein (ܳு௏). Finally, a fraction of the drug is excreted from the hepatocytes into the bile. 
The EHC implies that the bile produced in the liver is collected into the gall bladder, concentrated and 
introduced at the beginning of the ܵܫܮ tract. This process occurs cyclically during digestion phases and 
produces a singular effect on the drug. In fact, the bile carries along a fraction of the drug that, being reemitted 
in the ܵܫܮ, goes through a second intestinal absorption. This extends the drug life time in the body. 
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The drug fraction remaining in the blood flux, reaches the Plasma compartment through the ܳு௏ term. This 
compartment symbolizes the liquid fraction of the blood and is responsible for the drug transport in the body. 
The organs and tissues of the body which are not explicitly considered are lumped either in the 
Highly-perfused-Organs (ܪܱ) compartment, or in the Poorly-perfused-Tissues (ܲܶ) compartment. The drug 
mass transfer between plasma and these two compartments is evaluated by means of four mass transfer 
coefficients (i.e. ݇௉ି௉் and ݇௉ିுை from plasma into the respective compartment, and ݇௉்ି௉ and ݇ுைି௉ for the 
back transport of the drug into the plasma). Given this theoretical background, which is strongly based on 
mammalian anatomy and physiology, the related equations can be inferred naturally as dynamic mass 
balances describing the drug flow in every compartment. The resulting ODE system is: 
݀ܥீ௅(ݐ)
݀ݐ = −ீܨ ௅(ݐ) 
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(11) 
Here the differential terms assess the drug accumulation in the specific compartments. On the right hand side 
of ODEs positives terms enter the compartment while negative ones leave it. 
In detail, Eq.s (1-5) describe the transit through the gastrointestinal tract, specifically Eq. (2) refers to the first 
CSTR discretizing the ܵܫܮ, Eq. (3) to the generic intermediate CSTR, and Eq. (4) to the last CSTR of the ܵܫܮ. 
Eq.s (6-11) refer respectively to Plasma, Poorly perfused Tissues, Gastro-Intestinal Circulatory System, Liver, 
Highly perfused Organs, and Gall Bladder compartments. Table 1 details the terms characterizing the ODEs 
system. 
Table 1: Model parameters. 
Symbol Units Description Value 
ܧ݂ ு݂	 - Hepatic efficiency of elimination 0.018 
ܧ݂ ௄݂	 - Kidneys efficiency of elimination 0.014 
ܳீ஻	௜௡	 ml/min Bile volumetric flux to Gall Bladder 0.037 
ܳீ஻	௢௨௧	 ml/min Bile volumetric flux leaving Gall Bladder 0.001 
ܳு஺*	 ml/min Hepatic Artery volumetric flux 0.133 
ܳு௏*	 ml/min Hepatic Vein volumetric flux 1.078 
ܳ௄*	 ml/min Plasma volumetric flux to kidneys 0.605 
ܳ௉௏*	 ml/min Portal Vein volumetric flux 0.945 
ܸீ ஻*	 cm3 GB compartment volume 0.04 
ܸீ ூ஼ௌ*	 cm3 ܩܫ. ܥ. ܵ. compartment volume 0.005 
ܸீ ௅*	 cm3 Gastric Lumen compartment volume 1 
ுܸை*	 cm3 Highly perfused Organs compartment volume 1.48 
௅ܸ*	 cm3 Liver compartment volume 1.51 
௅ܸூ௅*	 cm3 ܮܫܮ compartment volume 0.29 
௉ܸ*	 ml Plasma compartment volume 1.28 
௉்ܸ*	 cm3 Poorly perfused Tissues compartment volume 18.22 
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Table 2: Model parameters (cont.d). 
Symbol Units Description Value 
ௌܸூ௅*	 cm3 ܵܫܮ compartment volume 0.76 
݇஺,௅ூ௅*	 min-1 ܮܫܮ to ܩܫ. ܥ. ܵ. mass transfer coefficient 0 
݇஺,ௌூ௅	 min-1 ܵܫܮ to ܩܫ. ܥ. ܵ. mass transfer coefficient 0.034 
݇஼஺,௅ூ௅*	 min-1 ܩܫ. ܥ. ܵ. to ܮܫܮ counter mass transfer coefficient 0 
݇஼஺,ௌூ௅	 min-1 ܩܫ. ܥ. ܵ. to ܵܫܮ counter mass transfer coefficient 0.082 
݇ா,௉	 min-1 Plasma Elimination mass transfer coefficient 0.051 
݇ுைି௉	 min-1 Highly perfused Organs to Plasma mass transfer coefficient 0.038 
݇௉ିுை	 min-1 Plasma to Highly perfused Organs mass transfer coefficient 0.215 
݇௉ି௉்	 min-1 Plasma to Poorly perfused Tissues mass transfer coefficient 0.482 
݇௉்ି௉	 min-1 Poorly perfused Tissues to Plasma mass transfer coefficient 0.012 
݇௟௣	 - Liver-Plasma partition coefficient 1.9 
݇௣௟*	 - Plasma-Liver partition coefficient (݇௟௣ reciprocal) 0.52 
ݐீ௅*	 min ܩܮ residence time 100 
ݐ௅ூ௅*	 min ܮܫܮ residence time 210 
ݐௌூ௅*	 min ܵܫܮ residence time 160 
ܣܿݐܤ݈݅݁* min Time corresponding to gall bladder emptying into the ܵܫܮ 260 
௨݂	 - Drug fraction unbound to plasma proteins 0.28 
*these values were assigned from literature data, other values were estimated via a nonlinear regression 
procedure respect to experimental data. Here ܥܮ௜ are defined as ܳ௜ ∙ ܧ݂ ௜݂, where ܳ is the plasma flux to the 
organ ݅ and ܧ݂݂ is related drug removal efficiency. One should observe that ܳீ஻	௜௡ is evidently an 
overestimation of the real value, but two aspects should be taken into account: (i) the drug concentration in the 
bile is assumed equal to the one in the liver, while it should be higher as an effect of drug excretion from the 
liver into the bile; (ii) the bile delivered to the gall bladder is diluted and is concentrated into the gall bladder 
itself. Unfortunately, at our knowledge more accurate experimental data are not available. 
4. Results 
The proposed PBPK model was applied to the description of the sorafenib pharmacokinetics in mice. 
Reference experimental data were the ones published by Pawaskar et al. (2013). In that study 20 mg/kg were 
administered in a single dose to male BALB/c mice (7 - 8 weeks old, average weight 25 - 30 g). 
Figure 2 shows the model outcomes. 
 
Figure 2: Dynamics of sorafenib concentration in four different representative compartments as predicted by 
the model (continuous line) respect to experimental data (points with standard deviation). 






























































































The model is able to describe the PK behavior of sorafenib in mice. Interestingly, the experimental 
concentrations are assessed with good fidelity for both organs and tissues. This aspect is of fundamental 
importance since it valorizes the application of anatomy and physiology to model based PK. Furthermore, the 
possibility to determine accurately the sorafenib concentration in the liver is fundamental as this drug is 
intended to act specifically on HCC. Finally, it is worth observing that the apparent overestimation of 
concentration in the PT compartment, should take into account that experimental values refer exclusively to 
drug concentration in the skin while PT refers to a larger set of tissues (e.g., muscles) which reasonably 
account for higher drug concentration respect to skin. 
5. Conclusions 
A PBPK model capable to describe sorafenib pharmacokinetics in mice was presented and discussed. The 
model implements some innovative aspects as the description of the EHC, which is responsible for the double 
peak profile in sorafenib concentration-time diagrams. The similarity of mammalian anatomy and physiology 
between mice and men is a promising feature that could allow exploiting the predictive features of the 
proposed model for sorafenib treatments in human patients. 
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